NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases.
NervGen Pharma has raised $60.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
NervGen Pharma's investors include U.S. Department of Defense, CSBio, SCI Ventures, PFP Biosciences, Paul and Phyllis Fireman Charitable Foundation.
NervGen Pharma is headquartered in Vancouver, Canada.
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases.
NervGen Pharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NervGen Pharma — Funding & Investors." VCBacked, May 21, 2026, https://www.vcbacked.co/company/nervgen-pharma. Accessed September 30, 2026.
VCBacked. (2026). NervGen Pharma — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/nervgen-pharma
{{cite web |title=NervGen Pharma — Funding & Investors |url=https://www.vcbacked.co/company/nervgen-pharma |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated